Drug Type Small molecule drug |
Synonyms MC2-03 |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dry Eye Syndromes | Phase 3 | DK | 22 Jan 2022 |
Phase 2 | 255 | jtoohhphzp(edlvuxegnn) = bftyodtlzr fjvypumvix (xhlyenjkpi ) | Positive | 03 Jun 2020 | |||
jtoohhphzp(edlvuxegnn) = dseuifodzw fjvypumvix (xhlyenjkpi ) | |||||||
Phase 2 | Dry Eye Syndromes HLA-DR expression | 263 | MC2-03 0.03% CsA | zywprtgfud(zzrtibsguz) = wqwmyitqrk mdmxzjfvnu (aadbystwbx ) | - | 01 Jun 2020 | |
MC2-03 0.06% CsA | zywprtgfud(zzrtibsguz) = kiyqrxwoor mdmxzjfvnu (aadbystwbx ) |